Combination immunotherapy shows significant benefits in liver cancer patients with cirrhosis, suggesting new treatment possibilities.
Immunotherapy has historically been restricted to HCC patients with well-preserved liver function, based upon safety and efficacy data established in clinical trial populations. While an immune-suppressive microenvironment coupled with comorbid cirrhosis may contribute to poorer outcomes, a subset of patients with worse degrees of liver function achieves significant clinical benefit from combination immunotherapy.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: